TULIP study: Trail of Lurasidone in bipolar disorder in Pakistan

This study examined usefulness and efficiency of Lurasidone in appraisal with the placebo as for the treatment of Bipolar Disorders. Seven treatment centers in Pakistan were selected for the purpose of starting a six week-long control trial (randomized and double-blind placebo). 76 subjects, already...

Full description

Saved in:

Bibliographic Details
Published in:	Saudi journal of biological sciences Vol. 28; no. 1; pp. 1128 - 1132
Main Authors:	Khan, Nasar, Nasar, Amina, Bajwa, Saqib, Jawad Butt, Aisha, Azher, Afia, Mushtaq, Tehmina, Rashid, Alina, Haq, Mian Mukhtar Ul, Rasul, Ghulam, Dogar, Firasat Ali
Format:	Journal Article
Language:	English
Published:	Saudi Arabia Elsevier B.V 01-01-2021 Elsevier
Subjects:	Bipolar affective disorders Lurasidone Mania Original Pakistan Mania Bipolar affective disorders Lurasidone Pakistan
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	This study examined usefulness and efficiency of Lurasidone in appraisal with the placebo as for the treatment of Bipolar Disorders. Seven treatment centers in Pakistan were selected for the purpose of starting a six week-long control trial (randomized and double-blind placebo). 76 subjects, already diagnosed with Bipolar I or II based on DSM 5 diagnosis, were selected after randomization. Patients were allocated in one of the two groups. Primary efficacy of the drug was measured using Young Mania Rating Scale. Positive response of the drug was defined as 50% reduction in symptoms from the baseline/13 point less than the baseline score on Young Mania Rating Scale. Efficacy and safety of the drug was assessed using variety of markers such as administering extra-pyramidal symptoms rating scale, adverse side effects reported, electrocardiograms, body weight, vital signs changes, and laboratory investigations. Patients treated with Lurasidone showed enhanced improvement in their overall health and symptoms manifestation in comparison to patients who were given placebo. Lurasidone treated patients showed a better response to the drug (66%), in comparison with the placebo treated patients (42%). Study was conducted on small scale due to complexity. Patients treated with Lurasidone showed reduction in bipolar symptoms and tolerate the drug well.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1319-562X 2213-7106
DOI:	10.1016/j.sjbs.2020.11.044